Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
March 1, 2017 6:35 AM ESTRBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a Outperform rating amid conservative guidance.
Analyst Simos Simeonidis commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT... More
Sarepta Therapeutics (SRPT) Misses Q4 EPS by 29c, Sales Beat
February 28, 2017 4:46 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.62), $0.29 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $5.42 million versus the consensus estimate of $4.72 million.
2016 was a transformative year, with the FDA accelerated approval of EXONDYS 51. In 2017, we are focused... More
